HIND (Vyome Holdings) Asset Turnover: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HIND Vyome Holdings Inc HIND
11 GF Score
Price $2.05
! 2 Warning Signs
View Full Analysis

What is Vyome Holdings Asset Turnover?

Vyome Holdings HIND +2.89% 11 Asset Turnover is 0.00 as of Mar. 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Vyome Holdings's Revenue for the three months ended in Mar. 2026 was $0.03 Mil. Vyome Holdings's Total Assets for the quarter that ended in Mar. 2026 was $8.34 Mil. Therefore, Vyome Holdings's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Vyome Holdings's annualized ROE % for the quarter that ended in Mar. 2026 was -83.87%. It is also linked to ROA % through Du Pont Formula. Vyome Holdings's annualized ROA % for the quarter that ended in Mar. 2026 was -46.18%.


Vyome Holdings  (NAS:HIND) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Vyome Holdings's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-3.852/4.593
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.852 / 0.128)*(0.128 / 8.341)*(8.341/ 4.593)
=Net Margin %*Asset Turnover*Equity Multiplier
=-3009.38 %*0.0153*1.816
=ROA %*Equity Multiplier
=-46.18 %*1.816
=-83.87 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Vyome Holdings's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-3.852/8.341
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-3.852 / 0.128)*(0.128 / 8.341)
=Net Margin %*Asset Turnover
=-3009.38 %*0.0153
=-46.18 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Vyome Holdings Asset Turnover Related Terms


Vyome Holdings Asset Turnover Historical Data

* Premium members only.

The historical data trend for Vyome Holdings's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vyome Holdings Asset Turnover Chart

Vyome Holdings Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Asset Turnover
0.21 0.26 0.18 0.08

Vyome Holdings Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.03 0.01 0.01 0.00

HIND vs CTXR, MBRX, AKTX: Asset Turnover Comparison

For the Biotechnology subindustry, Vyome Holdings's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vyome Holdings Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vyome Holdings's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Vyome Holdings's Asset Turnover falls into.


HIND
11GF Score
Vyome Holdings Inc HIND
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vyome Holdings Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Vyome Holdings's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=0.32/( (1.382+6.497)/ 2 )
=0.32/3.9395
=0.08

Vyome Holdings's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.032/( (6.497+10.185)/ 2 )
=0.032/8.341
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.00 mean?
Vyome Holdings (HIND) has a Asset Turnover of 0.00 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Vyome Holdings and its competitors.
Is Vyome Holdings' Asset Turnover too high?
Vyome Holdings' current Asset Turnover is 0.00. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' Asset Turnover compare to CTXR and MBRX?
Vyome Holdings' Asset Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Vyome Holdings and its competitors. Vyome Holdings's current Asset Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current Asset Turnover of 0.00. The current Asset Turnover is 0.00. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Vyome Holdings (HIND), the current Asset Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vyome Holdings Business Description

Address Harvard Square, Suite 400, One Mifflin Place, Cambridge, MA, USA, 02138
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score

Get the complete analysis for HIND

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.05
Price